NewsRoom Articles - BioMedWire (BMW)

TuesdayJun 16, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Working to Help Employers Tackle Cardiovascular Risk, Healthcare Costs

Cardiovascular disease remains one of the most expensive health conditions in the United States. Cardio Diagnostics announced plans to participate in four national benefits conferences during June. The company has developed a suite of solutions designed to provide earlier identification of cardiovascular risk and enable more targeted interventions and preventive care. A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient’s health, affecting employers, insurers and healthcare systems through higher medical costs, lost productivity and long-term care expenses. As cardiovascular disease continues to drive a significant share of healthcare spending, organizations responsible for…

TuesdayJun 16, 2026 10:00 am

How Authorities are Protecting Public Health During the FIFA World Cup

The FIFA World Cup started on June 11 and will end on July 19. 48 national teams are taking part, and this is an extra 16 teams when compared to the number of national teams that participated in the last edition that took place in Qatar in 2022. 100 matches are scheduled to be played across the U.S., Mexico and Canada. An international sporting event of this magnitude presents a major challenge to public health planners, and authorities have been working fervently to put in place measures geared at keeping infectious disease risks at bay during the tournament. We discuss…

FridayJun 12, 2026 10:00 am

Study Links TBI to Higher Mortality Risk Due to Brain Cancer

A study conducted by a team at Mass General Brigham has found that people with a history of traumatic brain injury had a higher chance of dying as a result of brain cancer. The findings create an urgency to rethink how TBI cases are handled not just in the immediate aftermath but also over the long term. The study, whose findings were published in the journal Neuroepidemiology, analyzed a national database of more than 20,000 patients who had been treated for traumatic brain injury over a period of 37 years (1987–2024). The investigators were especially interested in finding out how a history of TBI impacted mortality risk in brain cancer,…

FridayJun 12, 2026 9:45 am

Earth Science Tech Inc. (ETST) Reports Transformational Fiscal Year as Share Repurchases and Healthcare Expansion Shape Growth Strategy

Earth Science Tech, a growing holding company focused on various aspects of the healthcare industry, reported a series of operational milestones in its fiscal year ended March 31, 2026, highlighted by expansion across its healthcare platform and continued cash-flow generation. Earth Science Tech repurchased and retired more than 6.9 million shares of common stock since fiscal Q1 2026, underscoring management’s focus on reducing share dilution in support of shareholder value. Key operating businesses, including DOConsultation, Villas Health and MOC Teledoc, are now cash-flow positive. Peaks Curative surpassed $2 million in revenue during the first week of fiscal Q4 2026, reflecting…

ThursdayJun 11, 2026 10:00 am

FIU Researchers Discover New Way of Extending Immune Cell Lifespan and Effectiveness

CAR-T therapy has been transformational in treating many blood cancers, such as leukemia and lymphoma. However, this treatment approach hasn’t worked for solid tumors, and it also reaches a point and becomes ineffective in blood cancers. A new study just found a way to boost the lifespan and efficacy window of these important immune cells that help fight cancer. The study, whose findings appeared in the journal Frontiers in Immunology, was conducted by a team at Florida International University (FIU). The researchers spent about five years studying why cancer-fighting immune cells lose their effectiveness and don’t survive for long. They were particularly interested in establishing how tumor cells develop a protective mechanism against the immune cells…

ThursdayJun 11, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’

VERAXA is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. The company’s proprietary BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity. Through its focus on ADCs and TCEs, VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market. Via selected partnerships, VERAXA aims to contribute value to developments in complementary therapeutic sectors such as radioimmunoconjugates (“RICs”) and antibody-oligonucleotide conjugates (“AOCs”). VERAXA Biotech has successfully concluded a business combination…

WednesdayJun 10, 2026 9:00 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Is ‘One to Watch’

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. Onco-Innovations is developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company is positioning itself as a leader in the emerging PNKP inhibitor class, a segment of the broader DNA Damage Response therapy market that is distinct from established PARP inhibitor therapies. Five patents protect the company’s PNKP inhibitor technology, nanoparticle delivery platform and related applications, supporting its intellectual property position as development advances. Through its wholly owned subsidiary Inka Health, Onco-Innovations has…

TuesdayJun 09, 2026 10:00 am

Hospitals Take the Lead in Tackling Health Care Access and Affordability

Hospitals have come under the spotlight as public concern about the health care cost crisis reaches unprecedented levels. The president of the American Hospital Association (AHA) wrote an article last week outlining how hospitals are taking steps to ensure that access and affordability issues are addressed so that Americans can continue to enjoy the high quality of care that they have come to expect from the health care system. Rick Pollack explained that hospitals face numerous challenges, such as having to absorb a sizeable fraction of the increasing cost of providing medical services to Americans. This comes as reimbursements for programs like Medicare and Medicaid haven’t risen…

MondayJun 08, 2026 9:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body. The company announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated. Quantum BioPharma reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food…

FridayJun 05, 2026 10:30 am

Oncotelic Therapeutics Inc. (OTLC) Combines Nanomedicine, AI, and Robotics to Advance Precision Oncology and Rare Disease Innovation

OTLC continues to advance its Deciparticle nanomedicine platform, with expanding international development initiatives supporting future therapeutic and commercial opportunities. The company’s PDAOAI ecosystem now incorporates 28 million scientific abstracts and is being deployed into real-world pharmaceutical automation applications through TechForce Robotics. The company is leveraging AI, nanomedicine, and automation to accelerate therapies for cancer and rare diseases. Oncotelic Therapeutics (OTCQB: OTLC) is strategically placing itself at the nexus of precision oncology, advanced automation, and artificial intelligence. Through its PDAOAI artificial intelligence ecosystem, Deciparticle(TM) nanomedicine platform, and emerging robotics initiatives, the company is quickly building an integrated technology portfolio built to improve…